Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2021-05-31
Target enrollment:
Participant gender:
Summary
This is a first-in-human, Phase I, multicenter, open label, dose escalation study to evaluate
the DLTs and MTD and to determine the recommended Phase 2 dose (RP2D) of CPX-POM administered
IV in patients with any histologically- or cytologically-confirmed solid tumor type.